07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Toll-like receptor 2 (TLR2); CD14 Patient sample...
07:00 , May 16, 2013 |  BC Innovations  |  Cover Story

Eritoran insight for influenza treatment

A University of Maryland School of Medicine team has used a toll-like receptor 4 antagonist to treat influenza in mice.1 The results provide a repurposing opportunity for Eisai Co. Ltd.'s toll-like receptor 4 blocker Eritoran,...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Panax Pharmaceutical Ltd., Sangen Pharmaceutical Co. deal

PANX and privately held Sangen will merge contingent upon the raising of $10-$15 million in a private direct offering. PANX's lead product is a tablet for clearing the colon prior to colonoscopy. PANX said the...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Cenicriviroc: Additional Phase IIb data

Additional data from the double-blind, double-dummy, U.S. and Puerto Rican Phase IIb Study 202 trial in 143 treatment-naïve patients with CCR-5-tropic HIV-1 infection showed that 76% of patients receiving once-daily 100 mg oral cenicriviroc plus...
08:00 , Jan 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Respiratory syncytial virus (RSV) CD14; lymphocyte antigen 96 (LY96; MD2) In vitro and in vivo studies...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Biotron preclinical data

In ex vivo monocytes from 18 HIV-positive patients, BIT225 significantly reduced HIV-1 release. The small molecule inhibitor of HCV p7 protein and HIV Vpu protein also reduced the spread of HIV-1 within CD14+...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Implicit Biosciences, Eli Lilly deal

Implicit acquired exclusive, worldwide rights to Eli Lilly's IC14 for an undisclosed sum, including cash and stock. Implicit expects to begin Phase II testing of the antibody against CD14 to treat acute lung...
08:00 , Feb 6, 2006 |  BioCentury  |  Product Development

Breathless opportunities

Treatment of asthma has remained essentially unchanged for years and focuses on alleviating symptoms rather than disease modification. In large part, the state of the art reflects inertia on the part of the dominant big...
07:00 , Apr 30, 2001 |  BioCentury  |  Tools & Techniques

Getting specific on sepsis

Many of the failed efforts to develop sepsis drugs have focused on broad inflammatory modulators. In fact, the only product to date that has shown success in Phase III trials that measure 28 day mortality...
07:00 , Jul 3, 2000 |  BioCentury  |  Tools & Techniques

Lilly's sepsis success

The gold standard for sepsis treatments is 28-day all-cause mortality in a Phase III study, an end point that has dashed the dreams of companies and investors for the better part of a decade. Eli...